Mucins and carbocisteine: respiratory protection
- Authors: Babak S.L.1, Gorbunova M.V.1, Malyavin A.G.1
-
Affiliations:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
- Issue: Vol 7, No 10 (2021)
- Pages: 160-168
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288709
- DOI: https://doi.org/10.18565/therapy.2021.10.160-168
- ID: 288709
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Sergey L. Babak
A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Email: sergbabak@mail.ru
MD, professor of the Department of phthisiology and pulmonology of the Faculty of general medicine
Marina V. Gorbunova
A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of RussiaPhD, associate professor of the Department of phthisiology and pulmonology of the Faculty of general medicine
Andrey G. Malyavin
A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Email: maliavin@mail.ru
MD, professor, professor of the Department of phthisiology and pulmonology, head of the Center for Respiratory Medicine.
References
- Janssen W.J., Stefanski A.L., Bochner B.S., Evans C.M. Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions. Eur Respir J. 2016; 48(4): 1201-14. doi: 10.1 183/13993003.00120-2015.
- Carlier F.M., de Fays C., Pilette C. Epithelial barrier dysfunction in chronic respiratory diseases. Front Physiol. 2021; 12: 691227. doi: 10.3389/fphys.2021.691227.
- Li X., Cao X., Guo M. et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020; 368: m234. doi: 10.1136/bmj.m234.
- Atanasova K.R., Reznikov L.R. Strategies for measuring airway mucus and mucins. Respir Res. 2019; 20(1): 261. doi: 10.1186/s12931-019-1239-z.
- Чучалин А.Г., Абросимов В.Н. Кашель. М: ГЭОТАР-Медиа. 2016; 152 с. [Chuchalin A.G., Abrosimov V.N. Cough. Moscow: GEOTAR-Media. 2016; 152 pp. (In Russ.)]. ISBN: 978-5-9704-3728-5.
- Chatterjee M., van Putten J.P.M., Strijbis K. Defensive properties of mucin glycoproteins during respiratory infections-relevance for SARS-CoV-2. mBio. 2020; 11(6): e02374-20. doi: 10.1128/mBio.02374-20.
- Hiemstra P.S., McCray P.B. Jr, Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J. 2015; 45(4): 1150-62. doi: 10.1 183/09031936.00141514.
- Lillehoj E.P., Kato K., Lu W., Kim K.C. Cellular and molecular biology of airway mucins. Int Rev Cell Mol Biol. 2013; 303: 139-202. doi: 10.1016/B978-0-12-407697-6.00004-0.
- Bennett E.P., Mandel U., Clausen H. et al. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012; 22(6): 736-56. doi: 10.1093/glycob/cwr182.
- Okuda K., Chen G., Subramani D.B. et al. Localization of secretory mucins MUC5AC and MUC5B in normal/healthy human airways. Am J. Respir Crit Care Med. 2019; 199(6): 715-27. doi: 10.1164/rccm.201804-0734OC.
- Denneny E., Sahota J., Beatson R. et al. Mucins and their receptors in chronic lung disease. Clin Transl Immunology. 2020; 9(3): e01120. doi: 10.1002/cti2.1120.
- Hattrup C.L., Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008; 70: 431-57. doi: 10.1146/annurev.physiol.70.1 13006.100659.
- Yang D., Xing Y., Song X., Qian Y. The impact of lung microbiota dysbiosis on inflammation. Immunology. 2020; 159(2): 156-66. doi: 10.1111/imm.13139.
- Balsamo R., Lanata L., Egan C.G. Mucoactive drugs. Eur Respir Rev. 2010; 19(1 16): 127-33. doi: 10.1 183/09059180.00003510.
- Papi A., Avdeev S., Calverley P.M.A. et al. Use of mucolytics in COPD: A Delphi consensus study. Respir Med. 2020; 175: 106190. doi: 10.1016/j.rmed.2020.106190.
- Hooper C., Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J. Chron Obstruct Pulmon Dis. 2008; 3(4): 659-69.
- Colombo B., Turconi P., Daffonchio L. et al. Stimulation of Cl-secretion by the mucoactive drug S-carboxymethylcysteine-lysine salt in the isolated rabbit trachea. Eur Respir J. 1994; 7(9): 1622-28. doi: 10.1183/09031936.94.07091622.
- Maccio A., Madeddu C., Panzone F., Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother. 2009; 10(4): 693-703. doi: 10.1517/14656560902758343.
- Carpagnano G.E., Resta O., Foschino-Barbaro M.P. et al. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J. Pharmacol. 2004; 505(1-3): 169-75. doi: 10.1016/j.ejphar. 2004.10.007.
- Dicpinigaitis P.V. Review: Effect of drugs on human cough reflex sensitivity to inhaled capsaicin. Cough. 2012; 8(1): 10. doi: 10.1 186/1745-9974-8-10.
- Suer E., Sayrac S., Sarinay E. et al. Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J. Infect Chemother. 2008; 14(4): 333-36. doi: 10.1007/ s10156-008-0626-z.
- Ndour C.T., Ahmed K., Nakagawa T. et al. Modulating effects of mucoregulating drugs on the attachment of Haemophilus influenzae. Microb Pathog. 2001; 30(3): 121-27. doi: 10.1006/mpat.2000.0417.
- Braga P.C., Scaglione F., Scarpazza G. et al. Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J. Clin Pharmacol Res. 1985; 5(5): 331-40.
- Yasuda H., Yamaya M., Sasaki T. et al. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J. 2006; 28(1): 51-58. doi: 10.1 183/09031936.06.00058505.
- Мизерницкий Ю.Л., Ермакова И.Н. Современные мукоактивные препараты в терапии острых респираторных заболеваний у детей. Педиатрия. Приложение к журналу Consilium Medicum. 2007; 1: 53-56.
- Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371(9629): 2013-18. doi: 10.1016/ S0140-6736(08)60869-7.
- Zeng Z., Yang D., Huang X., Xiao Z. Effect of carbocisteine on patients with COPD: a systematic review and metaanalysis. Int J. Chron Obstruct Pulmon Dis. 2017; 12: 2277-83. doi: 10.2147/COPD.S140603.
- Minov J., Stoleski S., Petrova T. et al. Effects of a long-term use of carbocysteine on frequency and duration of exacerbations in patients with bronchiectasis. Open Access Maced J. Med Sci. 2019; 7(23): 4030-35. doi: 10.3889/ oamjms.2019.697.
Supplementary files
![](/img/style/loading.gif)